Brought to you by 
Anadys nets $44mm with IPO
22 Aug 2006
Executive Summary
Anadys Pharmaceuticals (develops small-molecule antibacterial and antiviral therapeutics) netted $44mm (including the overallotment) through its initial public offering of 6.99mm shares priced at $7 each. The company originally filed in November, hoping to raise $86.25mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Anadys nets $44mm with IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice